Clinical trials: Immunosuppressive Treatment
Kidney Transplantation
Rituximab for Prevention of Rejection After Renal Transplantation
Our standard immunosuppressive treatment after renal transplantation is a combination of tacrolimus, mycophenolate mofetil, and prednisolone.
- Trial name
- NCT00565331
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- Radboud University Medical Center
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medication Adherence
Medication Adherence in Kidney Transplant
Aims and Objective: The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
- Trial name
- NCT06004102
- Testing
- reminder text message
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Akdeniz University Hospital
COVID-19
Immunosuppression and COVID-19 Boosters
It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected.
- Trial name
- NCT05415267
- Testing
- diphtheria and tetanus toxoids (adsorbed) vaccine, COVID-19 vaccine
- Where
- 5 sites in Australia
- Volunteers
- 320 people
- Sponsor
- Kirby Institute
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
IgA Nephropathy at High Risk of Developing ESRD
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of…
- Trial name
- TCMWINE (NCT03418779)
- Testing
- The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects
This study used a single-center, randomized, open-label, three-period, crossover trial design. Fifteen healthy subjects were planned to be enrolled, and the subjects were randomly assigned to any group A, B and C in the order of…
- Trial name
- NCT06062680
- Testing
- Herombopag Olamine Tablets
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Uveitis, Cancer
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
This study will evaluate whether therapy that suppresses the immune system given to treat inflammatory diseases of the eye is associated with a greater risk of death and of cancer.
- Conditions
- Uveitis, Cancer, Infection, Mortality
- Trial name
- NCT00116090
- Where
- 4 sites in United States
- Volunteers
- 6,300 people
- Sponsor
- National Eye Institute (NEI)
Rheumatoid Arthritis, Exposed to TBE-virus
TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs
The investigators intend to check whether the efficacy of a TBE-vaccine is substantially deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress the immune system.
- Conditions
- Rheumatoid Arthritis, Exposed to TBE-virus, Immunosuppression
- Trial name
- NCT01131910
- Testing
- TBE-vaccine, Vaccination against TBE
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 68 people
- Sponsor
- Sormland County Council, Sweden
Crohn Disease (CD), Ulcerative Colitis (UC)
the REMONO-CD and the REMONO-UC Studies
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2.
- Trial name
- REMONO (NCT07564609)
- Where
- 18 sites in France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Clermont-Ferrand
Transplantation Infection, Cytomegalovirus Infection
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals.
- Trial name
- EVERCMV (NCT02328963)
- Testing
- Everolimus, mycophenolic acid
- Where
- 9 sites in France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Bordeaux
Asthma, Bronchial, Bronchial Asthma
Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
- Trial name
- NCT00189787
- Testing
- tacrolimus
- Where
- 49 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 370 people
- Sponsor
- Astellas Pharma Inc
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
SRL (Sirolimus) Withdrawal
The significance of this clinical trial lies in its potential to increase the success of immunosuppression (IS) therapy withdrawal in liver transplant (LT) recipients, thus decreasing the negative impact of IS on their long-term…
- Trial name
- SRL (NCT02062944)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Hepatitis, Autoimmune, Cholangitis
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents
- Conditions
- Hepatitis, Autoimmune, Cholangitis, Liver Cirrhosis, Biliary, Cholestasis
- Trial name
- NCT02936596
- Testing
- Ursodeoxycholic acid combination of immunosuppressive agents, Ursodeoxycholic Acid
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Xiaoli Fan
Vasculitis, Wegener's Granulomatosis
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
The aim of this trial is to lower the morbidity rate in elderly patients affected with systemic necrotizing vasculitides, by reducing mortality and improving global outcome.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome
- Trial name
- CORTAGE (NCT00307671)
- Testing
- prednisone, methylprednisolone,cyclophosphamides, Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, Mycophenolate mofetil,methotrexate
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections
Daclizumab to Treat HIV-Infected Patients
This study will examine the safety and effectiveness of daclizumab (also called Zenapax or anti-CD25) in reducing viral replication in patients with HIV infection.
- Trial name
- NCT00080431
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA)
Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome
This study will evaluate the safety and effectiveness of treating patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with both peripheral blood stem cells from a family member and umbilical cord blood…
- Trial name
- NCT00604201
- Testing
- Umbilical Cord Blood
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aplastic Anemia
A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
Severe acquired aplastic anaemia (SAA) is a bone marrow failure disease characterized by pancytopenia and a hypocellular bone marrow.
- Trial name
- OSP (NCT02203396)
- Testing
- rabbit ATG, Cyclosporine, Levamisole
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Idiopathic Thrombocytopenic Purpura
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level
1. The purpose of this study is to investigate the expression of CD11a on subpopulation of lymphocytes and compared its expression between ITP patients and healthy controls and explores its possible role in the pathogenesis of…
- Trial name
- NCT03864796
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University